Provided by Tiger Fintech (Singapore) Pte. Ltd.

Janux Therapeutics, Inc.

25.80
-0.4100-1.56%
Volume:296.12K
Turnover:7.73M
Market Cap:1.53B
PE:-18.90
High:27.00
Open:26.92
Low:25.50
Close:26.21
Loading ...

Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Sagimet Biosciences, Inc. Class A (SGMT) and Janux Therapeutics Inc (JANX)

TIPRANKS
·
03 Jun

Janux Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Corp. & Bus. Dev. Officer Janeen Noel Doyle

Reuters
·
24 May

Promising Developments and Market Potential of Janux Therapeutics Inc.: A Focus on JANX007 and JANX008 Trials

TIPRANKS
·
17 May

Stock Track | Janux Therapeutics Soars 5.04% on Appointment of New Chief Corporate and Business Development Officer

Stock Track
·
16 May

Janux appoints Janeen Doyle chief corporate, business development officer

TIPRANKS
·
15 May

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

Reuters
·
15 May

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

THOMSON REUTERS
·
15 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
13 May

Stock Track | Janux Therapeutics Soars 6.52% Pre-Market Following Analyst's Buy Rating

Stock Track
·
09 May

Promising Pipeline and Strategic Advancements Justify Buy Rating for Janux Therapeutics Inc

TIPRANKS
·
09 May

Buy Rating Affirmed for Janux Therapeutics: Promising Clinical Data and Superior Efficacy of Lead Program JANX007

TIPRANKS
·
09 May

Janux Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

BRIEF-Janux Therapeutics Q1 Basic EPS USD -0.38

Reuters
·
09 May

Janux Therapeutics Q1 Operating Income USD -34.897 Million

THOMSON REUTERS
·
09 May

Janux Therapeutics: $1.01 Billion in Cash, Cash Equivalents, and Short-Term Investments at End of Q1

THOMSON REUTERS
·
09 May

Buy Rating for Janux Therapeutics Inc. Driven by Strategic Advancements in Prostate Cancer Treatment with JANX007

TIPRANKS
·
07 May

Buy Rating for Janux Therapeutics Inc: Promising PFS Data and Attractive Valuation

TIPRANKS
·
06 May

Buy Rating for Janux Therapeutics Inc: Promising Clinical Trial Results and Positive Outlook for JANX007

TIPRANKS
·
06 May

Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential

Insider Monkey
·
05 May

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Illumina (ILMN)

TIPRANKS
·
05 May